Summary
The pharmacokinetics of colchicine has been studied in nine healthy male volunteers after oral doses of 0.5, 1, and 1.5 mg as tablets. Plasma and urine samples were collected over 48 h and analysed for colchicine by radioimmunoassay.
Individual colchicine concentration profiles in plasma and urine were well described by a two-compartment open model with zero-order input. Considering the absorption variables as specific to each experiment, the lag time (0–0.35 h) and duration (0.39–2.38 h) of absorption were found to be independent of dose, while the zero-order rate constant of absorption (k0) increased linearly with dose.
Disposition variables were taken as common to the three experiments, except in six subjects in whom renal excretion varied significantly across experiments in a dose-independent manner. For seven subjects the terminal half-life was 19.4 h, the oral apparent volume of distribution at steady-state (Vss/f) was 691 l, and the oral systemic clearance (CL/f) was 33.1 l·h−1. In the two other subjects, the values were unreliable, but the estimated terminal half-life was greater than 48 h, Vss/f ranged from 1690 to 3480 l, and CL/f was in the range of the other subjects in 1 subject, and it was about 15l·h−1 in the other. In the latter subject, these estimates, together with the observation that plasma concentration reached a plateau at 2 to 5 h after ingestion, suggest enterohepatic cycling of colchicine.
Overall, the disposition of colchicine was linear in the dose range 0.5–1.5 mg, with a long terminal half-life, and absorption obeyed zero-order kinetics, with k0 proportional to dose.
Similar content being viewed by others
References
Alarcon-Segovia D, Ramos-Niembro F, de Kasep GI, Alcocer J, Perez Tamayo R (1979) Long-term evaluation of colchicine in the treatment of scleroderma. J Rheumatol 6: 705–712
Boruchow IB (1966) Bone marrow depression associated with acute colchicine toxicity in the presence of hepatic dysfunction. Cancer 19: 541
Bourdon R, Galliot M, Scherrmann JM (1980) Clinical pharmacology of colchicine. Second International Congress of Toxicology, Brussels (abstract 0.201)
Chen HSG, Gross JF (1979) Pharmacokinetics of drugs subject to enterohepatic cycling. J Pharm Sci 68: 792–794
Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine for familial Mediterranean fever: A doubleblind trial. N Engl J Med 291: 934–937
Dixon WJ, Brown MB, Engelman L, Frane JW, Hill MA, Jenrich RI, Toporek JD (1985) BMDP Statistical Software. University of California Press, Berkeley
Ertel N, Omokoku B, Wallace SL (1969) Colchicine concentrations in leukocytes. Arthritis Rheum 12: 293
Ertel NH, Mittler JC, Akgun S, Wallace SL (1976) Radioimmunoassay for colchicine in plasma and urine. Science 193: 233–235
Girre C, Scherrmann JM, Thomas G, Crouzette J, Fournier PE (1987) Dose dependence of the bioavailability of orally administered colchicine. In: Aiache JM, Hirtz J (eds) Proceedings of the III European Congress of Biopharmaceutics and Pharmacokinetics 3. University of Clermont-Ferrand Press, Clermont-Ferrand, pp 31–36
Halkin H, Dany S, Greenwald M (1980) Colchicine kinetics in patients with familial Mediterranean fever. Clin Pharmacol Ther 28: 82–87
Harrison LI, Gibaldi M (1976) Influence of cholestasis on drug elimination: Pharmacokinetics. J Pharm Sci 65: 1346–1348
Hazen PG, Michel B (1979) Management of necrotizing vasculitis with colchicine: improvement in patients with cutaneous lesions and Behçet's syndrome. Arch Dermatol 115: 1303–1306
Hufford CD, Collins C, Clark AM (1979) Microbial transformation and13C-NMR analysis of colchicine. J Pharm Sci 68: 1239–1243
Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, Eagen KA (1986) A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315: 1448–1454
Kershenobich D, Vargas F, Garcia-Tsao G, Tamayo RP, Gent M, Rojkind M (1988) Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318: 1709–1713
Reymond JPh, Steimer JL, Niederberger W (1988) On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 16: 331–353
Schermann JM, Boudet L, Pontikis R, Nguyen-Hoang-Nam, Fournier PE (1980) A sensitive radioimmunoassay for colchicine. J Pharm Pharmacol 32: 800–802
Steimer JL, Plusquellec Y, Guillaume A, Boisvieux JF (1982) A time-lag model for pharmacokinetics of drugs subject to enterohepatic circulation. J Pharm Sci 71: 297–302
Takigawa M, Miyachi Y, Uehara M, Tagami H (1982) Treatment of pustulosis palmaris et plantaris with oral doses of colchicine. Arch Dermatol 118: 458–460
Vilain J, Francheteau P, Steimer JL (1988) PHACIN: un logiciel pour la modélisation compartimentale et l'estimation de paramètres pharmacocinétiques. In: Gremy F (ed) Journées d'informatique médicale. Sauramps Medical, Montpellier, pp 112–122
Wallace SL, Omokoku B, Ertel NH (1970) Colchicine plasma levels. Implications as to pharmacology and mechanism of action. Am J Med 48: 443–448
Wallace SL, Ertel NH (1973) Plasma levels of colchicine after oral administration of a single dose. Metabolism 22: 749–753
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thomas, G., Girre, C., Scherrmann, J.M. et al. Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. Eur J Clin Pharmacol 37, 79–84 (1989). https://doi.org/10.1007/BF00609430
Issue Date:
DOI: https://doi.org/10.1007/BF00609430